Response assessment using [ 68 Ga]Ga‐PSMA ligand PET in patients undergoing systemic therapy for metastatic castration‐resistant prostate cancer-Reference-Cited by-同舟云学术

Response assessment using [ 68 Ga]Ga‐PSMA ligand PET in patients undergoing systemic therapy for metastatic castration‐resistant prostate cancer

Published:2019-10-15 Issue:1 Volume:80 Page:74-82
ISSN:0270-4137
Container-title:The Prostate
language:en
Short-container-title:Prostate

Author:

Grubmüller Bernhard¹²,Rasul Sazan³,Baltzer Pascal²⁴,Fajkovic Harun¹²,D'Andrea David¹,Berndl Florian¹,Maj‐Hes Agnes¹,Grubmüller Karl Hermann⁵,Mitterhauser Markus³⁶,Wadsak Wolfgang³⁷,Pfaff Sarah³,Shariat Shahrokh F.¹⁸⁹¹⁰¹¹,Hacker Marcus³,Kramer Gero¹,Hartenbach Markus²³^ORCID

Affiliation:

1. Department of UrologyMedical University of Vienna Vienna Austria

2. Working Group of Diagnostic Imaging in UrologyAustrian Society of Urology Vienna Austria

3. Division of Nuclear Medicine, Department of Biomedical Imaging and Image‐guided TherapyMedical University of Vienna Vienna Austria

4. Division of General and Pediatric Radiology, Department of Biomedical Imaging and Image‐guided TherapyMedical University of Vienna Vienna Austria

5. Department of Urology and AndrologyUniversity Hospital Krems, Karl Landsteiner University of Health Sciences Krems Austria

6. Ludwig Boltzmann Institute Applied Diagnostics Vienna Austria

7. Center for biomarker research in medicine, CBmed GmbH Graz Austria

8. Karl Landsteiner Institute of Urology and Andrology Vienna Austria

9. Department of UrologyUniversity of Texas Southwestern Dallas Texas

10. Division of Medical Oncology, Department of UrologyWeill Medical College of Cornell University New York New York

11. Department of Urology, Second Faculty of MedicineCharles University Prague Czech Republic

Publisher

Wiley

Subject

Urology,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pros.23919

Reference23 articles.

1. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer

2. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

3. Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3

4. Bone imaging in prostate cancer: the evolving roles of nuclear medicine and radiology

5. Tumor markers in prostate cancer I: Blood-based markers

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic Significance of Baseline Clinical and [68Ga]Ga-PSMA PET Derived Parameters on Biochemical Response, Overall Survival, and PSA Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer (mCRPC) Patients Undergoing [177Lu]Lu-PSMA Therapy;Nuklearmedizin - NuclearMedicine;2024-09-03

2. Correlation of [68Ga]Ga-PSMA PET/CT response and PSA decline in first-line enzalutamide for metastatic castration-resistant prostate cancer patients;European Journal of Nuclear Medicine and Molecular Imaging;2024-08-29

3. Impact of Circulating Tumor Cell–Expressed Prostate-Specific Membrane Antigen and Prostate-Specific Antigen Transcripts in Different Stages of Prostate Cancer;Clinical Cancer Research;2024-04-08

4. Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer;Annual Review of Medicine;2024-01-29

5. Standardized PSMA-PET Imaging of Advanced Prostate Cancer;Seminars in Nuclear Medicine;2024-01